Overall, these data suggested that the downregulation of PART1 can inhibit the proliferation and differentiation of Hep3B cells by targeting the hsa-miR-3529-3p/FOXC2 axis and thus hinder the occurrence and development of liver cancer. This evidence concerns the gene PART1 and liver cancer.